Navigation Links
Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
Date:2/18/2009

ABBOTT PARK, Ill., and WATERTOWN, Mass., Feb. 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration with a first-in-human study evaluating ABT-450, an oral protease inhibitor for the treatment of chronic HCV. The objectives of the trial include assessment of safety, tolerability and pharmacokinetics. ABT-450 was discovered as part of a worldwide alliance between Abbott and Enanta to discover, develop and commercialize protease inhibitors for the treatment of HCV.

"Hepatitis C is a serious global health concern, with 170 million people currently infected by six different HCV genotypes," said John M. Leonard, M.D., senior vice president, Global Pharmaceutical Research and Development, Abbott. "As a global leader in the development of antiviral therapies and diagnostics, Abbott is bringing its decades of antiviral experience, particularly with protease inhibitors, to this collaboration and to the fight against HCV."

"ABT-450 demonstrated favorable potency in vitro across various HCV genotypes and highly resistant strains," said Jay R. Luly, Ph.D., president and CEO of Enanta Pharmaceuticals. "We look forward to working with Abbott to advance ABT-450, and to our building a pipeline of HCV protease inhibitors that addresses this widespread disease."

Phase 1 Study Design

The Phase 1, double-blind, placebo-controlled study for ABT-450 announced today is a single, ascending oral dose trial in healthy volunteers.

About the Hepatitis C Virus

Hepatitis C is a liver disease affecting more than 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a per
'/>"/>

SOURCE Abbott; Enanta Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott Receives Complete Response Letter From FDA for Controlled-Release Hydrocodone With Acetaminophen
2. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
3. Continuous Treatment With Abbotts HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
4. Abbotts Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
5. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
6. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
7. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
8. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
9. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2
... 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... volunteer enrollment in its Phase II clinical trial for ... study,are expected to be available in early 2009., ... 210,adolescents, between the ages of 12 to 17, who ...
... Set for Sept. 29, LA JOLLA, Calif., ... ) today announced that data presented at the ... showed that, in,addition to meeting the primary endpoint ... lead AMPA/kainate-type glutamate receptor antagonist,tezampanel, demonstrated improvement on ...
Cached Medicine Technology:Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine 2Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine 3Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 2Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel 3
(Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert ... International and InHealth media is a global sales and communications firm that offers U.S. ... to continue our business relationship with Mr. Reid Eckert, as his interpretation of the ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... Falls Church, VA (PRWEB) , ... August 30, ... ... Practices, **FDAnews Webinar**, Sept. 15, 2015 — 1:30 p.m. – 3:00 p.m. EDT, ... it's much more than a simple digital handwritten signature. , Clinical ...
(Date:8/29/2015)... ... August 29, 2015 , ... It can be ... against dribbled urine and sweat. "In order to prevent these problems, I conceived ... ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s crotch. It ...
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available ... $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, the public ... regardless of the item’s selling price.” , With competitive pricing in the e-commerce market ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Corporation,(CRM:TSX-V) announced today that it has opened a Center ... the Company,s second in the,Miami area, one of many ... of the Pembroke Pines Center brings the Company,s total ... Institute of Health, the prevalence rate of,hemorrhoids in the ...
... C-Span did to open,the door on Congressional proceedings ... is doing for medical professionals via its live,coverage ... Today is the innovative source of medical news ... credit to,physicians and other clinicians., From March ...
... The Bill & Melinda Gates Foundation,announced today that ... first,round of Grand Challenges Explorations, a US$100 million ... Proposals will,be accepted online at http://www.gcgh.org/explorations ... to submit a proposal by May 15,2008., ...
... Softgel Supplements Formulated for Easy Swallowing and ... ... Many things in life are,hard to swallow, but your vitamins shouldn,t ... a new,way to fuel the body with a complete product line ...
... to reach out to,wounded soldiers, Retired Army Reserve Lieutenant ... uplifting and rejuvenating weekend,retreats -- offered at no cost ... and relaxation for soldiers hurt in Iraq and Afghanistan., ... Terrorists,these brave men and women are now embarking on ...
... 2008) Real-world use of a novel drug-eluting stent ... clinical outcomes, according to one-year data from a large ... on the sirolimus-eluting Excel stent, are being reported today ... Annual Scientific Sessions in Partnership with ACC i2 Summit ...
Cached Medicine News:Health News:CRH Medical Corporation opens new center in Pembroke Pines Florida 2Health News:MedPage Today(R) Provides First-Time Live Video Coverage of Medical Meeting Press Conferences 2Health News:Gates Foundation Now Accepting Proposals for Grand Challenges Explorations 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 2Health News:Nature Made(R) Changes the Way America Takes Vitamins 3Health News:Healing Wounds and Hearts: Warrior Weekend Helps Soldiers Relax and Recover 2Health News:Registry unveils 'real-world' data on novel excel stent 2
Inquire...
Remote Blower With Bag-In/Bag-Out Option...
Class II Type B1 Biological Safety Cabinet...
Built-in, motor-driven internal calibration mass for convenient Touch-key calibration. Also capable of touch-key calibration with external weights. Built-in RS232 Interface, Shimadzu WindowsDirect ...
Medicine Products: